Latest:
Treatment Advances in HR+ Breast Cancer
A panel of experts who treat breast cancer close out a discussion on the use of newer therapies, including CDK4/6 inhibitors, based on outcomes demonstrated by recent clinical trials.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Sara L. Douglas, PhD, RN
Latest:
The Benefits for Nurses of Using Psychosocial Cancer Registry Data
Registries, large databases of patient information collected in a systematic, standardized fashion, most often focus on biologic measures, such as pathology, radiology, and laboratory results, to track incidence and prevalence of disease as well as causative factors.
Sara M. Tinsley, MS, PhD, ARNP, AOCN
Latest:
Sara Tinsley Discusses Quality of Life in Patients with High-Risk MDS
Sara M. Tinsley, MS, PhD, ARNP, AOCN, nurse practitioner, malignant hematology, Moffitt Cancer Center, discusses a study that examined quality of life in patients with high-risk myelodysplastic syndromes (MDS).
Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
Latest:
Treatment Advances in HR+ Breast Cancer
A panel of experts who treat breast cancer close out a discussion on the use of newer therapies, including CDK4/6 inhibitors, based on outcomes demonstrated by recent clinical trials.
Sara McLaughlin, MD
Latest:
Dr. McLaughlin on Lymphedema in Breast Cancer
Sara McLaughlin, MD, professor of Surgery, Mayo Clinic, discusses the frequency that lymphedema appears in patients with breast cancer and addresses the complications in identifying this after her presentation at the Lynn Sage Breast Cancer Symposium.
Sara Thier, PhD, MPH
Latest:
New Paradigm Emerging in Multiple Myeloma Therapy
The emerging treatment landscape for patients with high-risk multiple myeloma is burgeoning with new classes of drugs, novel agents, and fresh combination strategies that offer many promising and exciting options for future therapeutic approaches.
Sarah B. Goldberg, MD, MPH
Latest:
Dr Goldberg on the Investigation of VIC-1911 With/Without Sotorasib in KRAS G12C-Mutant NSCLC
Sarah Goldberg, MD, MPH, discusses the design and key objectives of an ongoing phase 1a/b study of VIC-1911 as a monotherapy and in combination with sotorasib in KRAS G12C–mutant non–small cell lung cancer.
Sarah E. Hoffe, MD
Latest:
Optimizing Advanced Technologies to Improve Outcomes in Esophageal Cancer
Studies have explored integration of chemotherapy, radiation therapy and surgery, with the suggestion that modern technologies may be changing the treatment landscape with better outcomes in esophageal cancer.